AstraZeneca released a press release today stating that their long-acting antibody (LAAB) combination, AZD7442, has been shown to reduce the risk of symptomatic Covid-19 by 77% in a clinical trial. The trial included many participants who had medical conditions placing them at greater risk of severe illness and those who had not been producing sufficient antibodies after vaccination.
Read More »This morning, the CDC released their Morbidity and Mortality Weekly Report focusing on third doses of the COVID-19 vaccine. The report referenced Pfizer’s Phase 3 clinical trial, which included 306 participants, ages 18-55, who received a booster dose. Doses were administered 5-8 months after completion of a primary series using mRNA vaccines. Adverse reactions were similar to those after the second dose, and “included mild to moderate injection site and systemic reactions” (1).
Read More »Last Friday, the WHO endorsed the use of Regeneron’s monoclonal antibody cocktail for patients at high risk of being hospitalized due to severe COVID-19. Others eligible for treatment include those unable to develop antibodies to COVID-19, through previous infection or vaccination. This includes immunocompromised persons. Regeneron’s casirivimab and imdevimab antibody cocktail, administered by infusion, was the first combination therapy to receive FDA EUA.
Read More »Earlier this week, the NIH announced that they are launching a new clinical trial to determine the antibody response of a booster dose in autoimmune disease patients who did not respond to an initial full dose of the COVID-19 vaccine.
Read More »